Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells

Proceedings of the National Academy of Sciences of the United States of America
C VitaleM C Mingari

Abstract

p75/AIRM-1 is a recently identified inhibitory receptor expressed by natural killer and myeloid cells displaying high homology with CD33. Crosslinking of p75/AIRM-1 or CD33 has been shown to sharply inhibit the in vitro proliferation of both normal myeloid cells and chronic myeloid leukemias. In this study, we analyzed acute myeloid leukemic cells for the expression of p75/AIRM-1. p75/AIRM-1 marked the M5 (11/12) and M4 (2/2) but not the M1, M2, and M3 subtypes according to the French-American-British classification. Cell samples from 12 acute myeloid leukemias were cultured in the presence of granulocyte/macrophage colony-stimulating factor. Addition to these cultures of anti-CD33 antibody resulted in approximately 70% inhibition of cell proliferation as assessed by [(3)H]thymidine uptake or by the recovery of viable cells. Anti-p75/AIRM-1 antibody exerted a strong inhibitory effect only in two cases characterized by a high in vitro proliferation rate. After crosslinking of CD33 (but not of p75/AIRM-1), leukemic cells bound Annexin V and displayed changes in their light-scattering properties and nucleosomal DNA fragmentation, thus providing evidence for the occurrence of apoptotic cell death. Remarkably, when anti-CD33 antibod...Continue Reading

References

Jul 1, 1991·The Journal of Experimental Medicine·M C MingariL Moretta
Jan 1, 1996·Annual Review of Immunology·A MorettaL Moretta
Jun 8, 1999·Annual Review of Immunology·E O Long
Nov 11, 1999·European Journal of Immunology·T UlyanovaM L Thomas
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·C VitaleM C Mingari

❮ Previous
Next ❯

Citations

Nov 24, 2011·Current Hematologic Malignancy Reports·Joseph G Jurcic
Sep 3, 2002·Life Sciences·Jin WuBurton B Yang
Sep 12, 2002·Biochimica Et Biophysica Acta·Takashi Angata, Els Brinkman-Van der Linden
Nov 17, 2001·Current Opinion in Pharmacology·L MorettaA Moretta
Apr 10, 2002·Scandinavian Journal of Immunology·L MorettaA Moretta
Feb 22, 2012·Science·Shawn M DouglasGeorge M Church
May 30, 2003·Molecular and Cellular Biology·Els C M Brinkman-Van der LindenAjit Varki
Jun 12, 2013·Frontiers in Bioscience (Landmark Edition)·Andrew J CowanRoland B Walter
May 9, 2014·Blood Reviews·George S LaszloRoland B Walter
Aug 28, 2004·Proceedings of the National Academy of Sciences of the United States of America·Takashi AngataAjit Varki
Aug 1, 2014·Theoretical Biology & Medical Modelling·Rafael Marcos Luque-BaenaJose M Jerez
Apr 1, 2013·Drug Delivery and Translational Research·Timothy E AndrewsDaniel A Harki
Nov 30, 2010·Best Practice & Research. Clinical Haematology·Edward D Ball, H Elizabeth Broome
Nov 17, 2009·Pharmacology & Therapeutics·Ariel Munitz
Apr 24, 2002·Clinical Lymphoma·Irwin D Bernstein
Oct 19, 2007·Cancer Treatment Reviews·Roberto StasiSergio Amadori
Apr 16, 2003·European Journal of Haematology·Régis T CostelloD Olive
Dec 17, 2008·Annals of the New York Academy of Sciences·Stephan von Gunten, Bruce S Bochner
Feb 13, 2010·IEEE/ACM Transactions on Computational Biology and Bioinformatics·Yukyee Leung, Yeungsam Hung
Sep 21, 2004·IEEE Transactions on Nanobioscience·Mari Ogiue-IkedaShoogo Ueno
Sep 26, 2006·Best Practice & Research. Clinical Haematology·Sergio Amadori, Roberto Stasi
May 27, 2006·Experimental Hematology·Dzung H NguyenAjit Varki
Feb 22, 2014·Bulletin du cancer·Thibault BrotelleRomain Guièze
Mar 15, 2018·Expert Opinion on Investigational Drugs·Roland B Walter
Aug 5, 2004·The Journal of Biological Chemistry·Yuzuru IkeharaJames C Paulson
Jul 14, 2006·European Journal of Immunology·Andrew S J MarshallGordon D Brown
Jul 15, 2005·Glycobiology·Ajit Varki, Takashi Angata

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.